FDA greenlights intravenous epilepsy drug

The Food and Drug Administration recently approved Deerfield, Ill.-based Lundbeck's new epilepsy drug Carnexiv.

The intravenous drug can be used as a short-term replacement therapy for patients with certain types of seizure disorders when oral administration of the drug is not possible.

San Diego, Calif.-based Ligand Pharmaceuticals, a partner of Lundbeck, will earn a $1.25 million milestone payment for the approval and is entitled to 2.75 percent of Carnexiv's net sales.

Lundbeck plans to launch Carnexiv in early 2017.

More articles on supply chain:

Southwest Airlines to haul international cargo next year
Dana-Farber, Brigham and Women’s in 'urgent need' of platelet donations
Southwest Airlines to haul international cargo next year

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars